BK vs PCRX · P/E 17, $94.14B cap vs P/E 174, rev $369.8M
The Bank of New York Mellon Corporation (BK) versus Pacira BioSciences, Inc. (PCRX) — a side-by-side from cached financials, not a winner call.
The Bank of New York Mellon Corporation (BK) is a banks - diversified company listed on US.
Pacira BioSciences, Inc. (PCRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
BK does not have a complete income-statement cache yet.
Latest reported PCRX revenue for 2026-06-30 was $369.8M. Net income was $7.6M. PCRX currently screens at market cap $890.8M and trailing P/E 174.2.
BK currently screens at market cap $94.14B and trailing P/E 17.0. PCRX currently screens at market cap $890.8M and trailing P/E 174.2.
Not investment advice. Open the BK and PCRX stock pages for the full models.
Not investment advice.